Lumos sets Q3 reporting date, investor webinar as SPP enters final stretch Proactive uses images sourced from Shutterstock

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has locked in the timing for its March quarter update and investor briefing, while reminding shareholders that its current capital raising is approaching its closing date.

The company will release its Q3 FY26 results on April 20, followed by an investor webinar on April 21, where management will outline quarterly performance and recent developments.

Q3 results and webinar timing confirmed

The webinar will be held online at 11:00 am (AEST) on April 21, with investors and analysts invited to attend. Participants can register at the following link: https://us02web.zoom.us/webinar/register/WN_LGuVX42cSH6Fq0asH0O5uw

The session is expected to provide further colour on the company’s operational progress, with a particular focus on commercial activity and execution across its diagnostics portfolio.

The update comes amid a period of increased activity for Lumos, including ongoing expansion efforts in the US for its flagship FebriDx test.

SPP enters final days

Alongside the quarterly update, Lumos is continuing its Share Purchase Plan (SPP), which opened on April 10 and is set to close on April 24 at 5 pm (AEST).

Key details of the offer include:

One free attaching option for every two shares subscribed Pricing aligned with the recent institutional placement Access to supporting materials via the company’s investor portal

The SPP follows a broader capital raising completed in late March and is aimed at giving existing shareholders an opportunity to participate on similar terms.

Commercial momentum building

While much of Lumos’ recent news flow sits outside the March quarter, it is likely to shape investor focus heading into the results.

In recent weeks, Lumos has expanded the deployment of FebriDx across additional urgent care sites in the US, secured a US$5 million milestone payment linked to regulatory progress, and continued building out manufacturing capacity.

These updates point to growing commercial traction as Lumos pushes further into the US market, continuing the transition from development to revenue generation.

The webinar also provides a timely touchpoint for management to engage with investors as the SPP nears completion, potentially supporting participation ahead of the closing date.

View Comments